Supplementary Methods. Supplementary Tables S1-7. Supplementary Figures S1 and S2 from Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

Supplementary Tables S1-7. Supplementary Table S1. Clinical characteristics of patients in the present analysis. Supplementary Table S2. Plasma/tissue concordance results for del19 and L858R mutations. Supplementary Table S3. EGFR mutations identified in tissue and plasma by the cobas® EGFR mutation test. Supplementary Table S4. Concordance between tumor and BEAMing plasma EGFR status. Supplementary Table S5. Overall concordance between cobas® and BEAMing EGFR mutation tests. Supplementary Table S6. Platform Comparison of T790M tests in a sample set enriched for low copy plasma cases. Supplementary Table S7. EGFR mutation detection by cobas® plasma test and NSCLC disease classification (n = 72) Supplementary Figures S1-2. Supplementary Figure S1. Tumor burden is a weak predictor of ability to detect EGFR mutations in plasma. Supplementary Figure S2. T790M to activating mutation ratio in plasma is associated with depth of response to rociletinib.